Mayo Clinic Connect
Researcher Keith Knutson, Ph.D., and oncologist Saranya Chumsri, M.D., discuss current breast cancer research and treatment options.
Learn more about:
It appears that after treatment of ER/PR + breast cancer treatment, the standard treatment for post-menopausal women is hormone suppression for 5-10 years and hope it does not recurred. This results in many side effects and anxiety.
Is there any new research being done to prevent or predict ER/PR + breast cancer recurrence?
Liked by Colleen Young, Connect Director, Audrey Laine Seymour
We're going to start in a few minutes. Dr. Chumsri was delayed with a patient.
I'm new to this. Can I listen live from my facebook page or do I go somewhere else?
My daughter has a PTEN mutation which places her more at risk for breast cancer. Is there anything she can/should be doing to help prevent breast cancer from occurring?
Hello! I am joining late. Has TNBC vaccine study opened back up yet? Thank you! I appreciate all you do for your patients here at Mayo in JAX.
To add to the previous question – the TNBC immunotherapy (not sure if this is the right word). study.
Jump to this post
You can find clinical trials at Mayo Clinic here: https://www.mayo.edu/research/clinical-trials.
Yes. But I am asking about the vaccine study that recently closed – however, according to Dr. Chumsri – it could possibly reopen.
I am a breast cancer survivor – diagnosed at age 52 – ER/PR positive. I have 2 adult daughters. What testing/care would you recommend to monitor them for breast cancer?
I was in a study for hormone suppression prior to surgery that measured Ki67. What is Ki67 and is it just a measurement in breast cancer or also in other cancer?
Hi Laurie, I sent your question to Dr. Chumsri. Here's her reply: Ki67 is a protein that expresses in any cells in the body that are dividing. It is not specific to breast cancer. Ki67 is often used in clinical trials to evaluate the ability of drugs to target proliferation in cancer.
version 220.127.116.11.6Page loaded in 17.455 seconds